NR3C2 and Hypertension: There is currently considerable interest in the use of combination treatment with an RAS inhibitor plus MR blocker to treat hypertension and improve renal outcomes in patients with diabetes [14, 24], and whether the renoprotective effects of MR blockers are independent of changes in blood pressure.